REG - OptiBiotix Health - Issue of Equity – Subscription

OptiBiotix HealthAnnouncement

05/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221205:nRSE5174Ia&default-theme=true

RNS Number : 5174I  OptiBiotix Health PLC  05 December 2022

 

OptiBiotix Health plc

("OptiBiotix” or the "Company”)

 

Issue of Equity - Subscription

Appointment of Joint Broker

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, cardiovascular disease, diabetes and skincare,
announces that the Company has raised £500,000 through the issue of 3,125,000
new ordinary shares of 2 pence each in the Company ("Ordinary Shares") at a
price of 16 pence per share (the "Subscription") handled by Peterhouse Capital
Limited.

 

The net proceeds of the Subscription will be utilised to invest in the
Company's direct-to-consumer ("D2C”) product model, in particular to drive
sales growth across the business and build partnerships in the USA and for
general working capital purposes.

 

Appointment of Joint Broker

Separately, the Company announces the appointment of Peterhouse Capital
Limited as joint broker to the Company with immediate effect.

 

Admission

Application will be made to the London Stock Exchange to admit the 3,125,000
new Ordinary Shares to trading on AIM ("Admission”). Admission of the new
Ordinary Shares is expected to occur on or around 9 December 2022. The new
Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue
of shares detailed above the enlarged issued share capital of the Company will
comprise 91,190,661 ordinary shares of 2p each. The above figure may be used
by shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company, under the Disclosure and Transparency Rules.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "I am pleased with the interest
shown from new and existing shareholders in this fundraise which will support
further company growth. The funds will support an acceleration of our direct
to consumer business, help expand our US partner network, and launch our
second generation products into the market.  These steps will help create
shareholder value and support OptiBiotix's position as a leader in the
microbiome field.”

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Joint Broker)              Tel: 020 7397 8900
 Callum Davidson
 Michael Johnson / Russell Kerr (Sales)

 Peterhouse Capital Limited (Joint Broker)         Tel: 020 7220 9797
 Duncan Vasey/ Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identiÞed by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions.  These forward looking statements are
not based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures (including the
amount, nature and sources of funding thereof), competitive advantages,
business prospects and opportunities. Such forward looking statements reßect
the Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEZZMGZRFZGZZM